TITLE

XOMA's Phase I Diabetes Data Suggest New Path for Therapy

AUTHOR(S)
Osborne, Randy
PUB. DATE
June 2009
SOURCE
BioWorld Today;6/9/2009, Vol. 20 Issue 109, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article discusses the data presented by XOMA Ltd. from a randomized trial conducted in Switzerland and the U.S. which tested effectiveness XOMA 052, a monoclonal antibody that binds to interleukin-1 beta, in treating patients with Type II diabetes. Findings of the study indicate that the drug could serve as an alternative to therapies that attempt to obtain more insulin out of pancreatic beta cells. The data presented influenced the increase of the company's stock price by 12 cents on June 8, 2009.
ACCESSION #
41535948

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics